MRNA Price Prediction Next Week
Based on the provided data and recent market developments, here's the analysis and price prediction for MRNA for the next trading week:
Technical Analysis
- RSI(14) at 36.91 indicates the stock is approaching oversold territory but not yet extremely oversold
- MACD at -1.65 shows strong bearish momentum
- Current price ($32.98) is trading significantly below SMA20 ($37.62), indicating a strong downtrend
Recent News Impact
- MRNA fell 17.30% last week, making it one of the top large-cap losers
- The company is in cost-cutting mode and has reduced its revenue guidance by around $1 billion, now expecting only $1.5-2.5 billion for the year
- Bird flu developments: MRNA is among companies developing new mRNA-based shots to combat bird flu, but this hasn't provided significant price support
Price Targets for Next Week Based on Fibonacci levels:
- Resistance levels: R1: $43.37, R2: $46.37, R3: $51.22
- Support levels: S1: $33.68, S2: $30.68, S3: $25.84
- Pivot: $38.53
Trading Recommendation: SELL Rationale:
- Significant downward momentum with weak fundamental outlook
- Revenue guidance reduction indicates continued business challenges
- Technical indicators show bearish trend continuation likely
- Price targets: Primary downside target $30.68 (S2), with potential for further decline to $25.84 (S3) if market sentiment remains negative
The stock is likely to continue its downward trend next week, with an estimated trading range between $25.84-$33.68. The probability of breaking above $38.53 (pivot) appears low given current market conditions and fundamental headwinds.
MRNA Similar Chart Price Prediction
The price of MRNA is predicted to go up 1.5%, based on the high correlation periods with ASML. The similarity of these two price pattern on the periods is 92.99%.
MRNA
ASML
Up: 1.5%Similarity: 92.99%
MRNA Revenue Forecast
MRNA EPS Forecast
MRNA FAQs
What is bull’s view on MRNA?
What is bear's view on MRNA?
What is MRNA revenue forecast for next quarter？
What is MRNA eps forecast for next quarter？
MRNA VS S&P500
The stellar efficacy and safety profile of Moderna's COVID-19 vaccine offered rapid validation of the firm's mRNA technology.
Its mRNA technology could allow the firm to compete in a wide range of therapeutic areas, from other prophylactic vaccines (like influenza and other viruses) to enzyme replacement (various rare diseases) to cancer.
Moderna's cash infusion from COVID-19 vaccine sales in 2021-22, as well as newly established large-scale manufacturing facilities, position the firm to accelerate timelines for new pipeline programs.
MRNA Analyst's Forecast
Matthew Harrison
Morgan Stanley
Hold
2025-01-15
Price Target
$70 → $38
Upside
+9.29%
Morgan Stanley analyst Terence Flynn lowered the firm's price target on Moderna to $38 from $70 and keeps an Equal Weight rating on the shares after the company announced 2024 product sales of $3.0B-$3.1B and also lowered 2025 revenue guidance to $1.5B-$2.5B from $2.5B-$3.5B. While the enterprise value of the stock appears to be pricing in about $2B-$2.5B in revenue, so the stock "could be settling into a support level," investors are likely to remain focused on commercial execution as Moderna competes against larger, more scaled companies in COVID, RSV markets and flu in the future, pipeline execution and spending levels.
Jessica Fye
JP Morgan
Sell
2024-11-26
Price Target
$59 → $45
Upside
+7.02%
Edward Tenthoff
Piper Sandler
Buy
2024-11-18
Price Target
$115 → $69
Upside
+74.64%
